

**Supplementary Table 3.** Sensitivity Analysis on Risk of Bleeding Events According to Exposure Definition as at Least 1-, 7-, 14-, and 30-Days Overlap within a NOAC Treatment Episode

	Case (n=1233)	Control (n=24660)	Crude OR (95% CI)	Adjusted OR (95% CI)*
<b>1 day</b>				
No use	632 (51.3)	14644 (59.4)	Ref	Ref
NSAIDs only	506 (41.0)	8985 (36.4)	1.36 (1.20–1.55)	1.39 (1.22–1.59)
SSRIs only	45 (3.6)	513 (2.1)	2.10 (1.53–2.88)	1.78 (1.28–2.49)
Both NSAIDs and SSRIs	50 (4.1)	518 (2.1)	2.32 (1.72–3.15)	2.67 (1.95–3.66)
<b>7 days</b>				
No use	736 (59.7)	16177 (65.6)	Ref	Ref
NSAIDs only	408 (33.1)	7504 (30.4)	1.23 (1.08–1.41)	1.29 (1.12–1.48)
SSRIs only	50 (4.1)	598 (2.4)	1.88 (1.39–2.54)	1.69 (1.23–2.32)
Both NSAIDs and SSRIs	39 (3.2)	381 (1.5)	2.31 (1.65–3.25)	2.83 (1.99–4.04)
<b>14 days</b>				
No use	844 (68.5)	17507 (71.0)	Ref	Ref
NSAIDs only	309 (25.1)	6262 (25.4)	1.03 (0.90–1.19)	1.07 (0.92–1.25)
SSRIs only	55 (4.5)	567 (2.3)	2.04 (1.53–2.72)	1.83 (1.34–2.48)
Both NSAIDs and SSRIs	25 (2.0)	324 (1.3)	1.61 (1.07–2.44)	2.01 (1.31–3.08)
<b>30 days</b>				
No use	844 (68.5)	17507 (71.0)	Ref	Ref
NSAIDs only	309 (25.1)	6262 (25.4)	0.95 (0.81–1.11)	0.97 (0.82–1.15)
SSRIs only	55 (4.5)	567 (2.3)	1.87 (1.36–2.56)	1.59 (1.14–2.22)
Both NSAIDs and SSRIs	25 (2.0)	324 (1.3)	1.99 (1.18–3.34)	2.21 (1.29–3.77)

OR, odds ratio; CI, confidence interval; NSAIDs, non-steroidal anti-inflammatory drugs; SSRIs, selective serotonin reuptake inhibitors; NOAC, non-vitamin K antagonist oral anticoagulant.

\*Adjusted for demographic characteristics, comedications (beta-blockers, calcium channel blockers, angiotensin II receptor antagonists, statins, diuretics), and comorbidities (myocardial infarction, dementia, liver/renal disease).